April 24, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Chris Edwards
| Re: | Acrivon Therapeutics, Inc. |
Registration Statement on Form S-3
File No. 333-278761
Acceleration Request
Requested Date: April 29, 2024
Requested Time: 9:00 A.M., Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Acrivon Therapeutics, Inc. (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-3, Registration Number 333-278761 (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 9:00 A.M., Eastern Time, on April 29, 2024, or as soon thereafter as practicable or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.
We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Nick DeAngelis of Sidley Austin LLP at (214) 969-3563 or ndeangelis@sidley.com.
Very truly yours,
/s/ Rasmus Holm-Jorgensen
Rasmus Holm-Jorgensen
Chief Financial Officer
Acrivon Therapeutics, Inc.
| cc: | Mary-Alice Miller, General Counsel and Corporate Secretary |
Istvan Hajdu, Sidley Austin LLP
Nick DeAngelis, Sidley Austin LLP